Marginum, a medtech startup based in Kuopio, Finland, has successfully secured €2.5M in pre-series A funding. This funding aims to advance the development of novel fluorescence-based tissue detection systems designed to assist in cancer surgeries. By aiding surgeons with real-time data, Marginum seeks to enhance surgical outcomes and address unmet clinical needs. The success of this funding round heralds a progressive step for both the company and the medical technology sector.
The recent developments add to past funding endeavors for Marginum, where it aims to enhance precision in oncological surgeries. Nostetta Ventures led the current funding round, marking the continuation of its support since previous rounds. New participants, including Lynx Financial, further enrich the diversity of investments, reflecting increased confidence in Marginum’s potential impacts on healthcare.
How Will Marginum Use the Funds?
With this new capital, Marginum plans to pursue FDA clearance for its HIVEN aspirate tissue monitoring device. Additionally, there is a strategic focus on expanding the reach of this innovative technology into more European markets. The funding will also support strategic hiring and bolster research and development efforts, reinforcing Marginum’s commitment to improving cancer treatment.
What Makes the HIVEN Device Stand Out?
The HIVEN device is designed to facilitate surgeons in identifying tumor cells during surgery via fluorescence. This system uses a fluorescent dye and provides near-instant feedback when cancer cells are detected, all while under normal surgical lighting. This technology offers surgeons a more accurate way to ensure the complete removal of tumor tissues.
Past tests have demonstrated promising outcomes at Oslo, Tampere, and Kuopio University Hospitals. The University of Eastern Finland’s research group, led by docent and consultant neurosurgeon Antti-Pekka Elomaa, has contributed foundational research to this technology. The company anticipates further application of this method in treating not only brain tumors but also ovarian, bladder, and liver cancers.
Marginum expects the HIVEN device to achieve EU market authorization by fall 2025, which will kick off sales in the Nordic countries. Alongside a distribution partner, Marginum is targeting significant sales growth in the coming years.
Marginum’s steps highlight ongoing efforts in enhancing cancer treatment technology. As initiatives like these unfold, they reflect a broader shift in medical innovations focused on providing effective and efficient solutions in healthcare. Understanding such technologies and their achievements is vital, as they potentially redefine surgical practices.
